Salmeterol superfine formulation
    13.
    发明申请
    Salmeterol superfine formulation 失效
    沙美特罗超细配方

    公开(公告)号:US20060120966A1

    公开(公告)日:2006-06-08

    申请号:US10531867

    申请日:2003-06-18

    摘要: The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

    摘要翻译: 本发明涉及用于通过吸入施用长效β2激动剂的药物制剂。 特别地,本发明涉及一种化学稳定,高效的沙美特罗HFA溶液制剂,其由以深肺渗透为特征的加压计量剂量吸入器(pMDI)施用。 本发明还涉及制备所述制剂及其在呼吸系统疾病如哮喘和慢性阻塞性肺疾病(COPD)中的应用的方法。